Unity Biotechnology Inc UBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if UBX is a good fit for your portfolio.
News
-
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
-
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
-
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
-
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
Trading Information
- Previous Close Price
- $1.48
- Day Range
- $1.47–1.52
- 52-Week Range
- $1.46–3.82
- Bid/Ask
- $1.50 / $1.52
- Market Cap
- $25.18 Mil
- Volume/Avg
- 38,503 / 92,934
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
Valuation
|
Metric
|
UBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.87 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
UBX
Financial Strength
|
Metric
|
UBX
|
|---|---|
Quick Ratio | 5.71 |
Current Ratio | 5.94 |
Interest Coverage | −16.43 |
Quick Ratio
UBX
Profitability
|
Metric
|
UBX
|
|---|---|
Return on Assets (Normalized) | −33.72% |
Return on Equity (Normalized) | −69.97% |
Return on Invested Capital (Normalized) | −38.56% |
Return on Assets
UBX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lnhhrfwxx | Qdzj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ydtspgvn | Htbdgvs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Drhzjjdmf | Cqhkkw | $97.8 Bil | |
MRNA
| Moderna Inc | Gqsfgjbd | Fmtfm | $41.3 Bil | |
ARGX
| argenx SE ADR | Nsqmrdt | Lgyxw | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Lqpcdlnd | Fgj | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kvqbyqk | Xkcgqt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ycphlrlv | Gxrpks | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Prdyttckc | Zvpjfx | $12.5 Bil | |
INCY
| Incyte Corp | Fnyzsznrg | Gsgrgr | $11.6 Bil |